Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21427036 | 0.84 | CES2 (0.46) | LMNATSHRMAPTL3MBTL1KDM4E | |
| SCHEMBL1529979 | 0.83 | DAO (0.54) | LMNAALDH1A1HPGDERN1RAB9A | |
| SCHEMBL1529992 | 0.81 | NPSR1 (0.56) | LMNATSHRMAPTL3MBTL1KDM4E | |
| SCHEMBL11450476 | 0.81 | LMNA (0.47) | LMNATSHRGSK3BMAPTL3MBTL1 | |
| SCHEMBL7862068 | 0.81 | DAO (0.38) | LMNATSHRGSK3BMAPTL3MBTL1 | |
| SCHEMBL11605691 | 0.79 | CPT1B (0.47) | LMNAMAPTKDM4EALDH1A1GLA | |
| SCHEMBL14997447 | 0.79 | LMNA (0.46) | LMNATSHRGSK3BMAPTL3MBTL1 | |
| SCHEMBL1763294 | 0.79 | LMNA (0.46) | LMNATSHRGSK3BMAPTL3MBTL1 | |
| SCHEMBL3411329 | 0.79 | LMNA (0.46) | LMNATSHRGSK3BMAPTL3MBTL1 | |
| SCHEMBL2872059 | 0.78 | GSK3B (0.67) | LMNATSHRGSK3BMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2025-08-14 | — | — | US | disclosed |
| US-20250179243-A1 | MAIN CHAIN POLYMER, OPTICAL FILM, METHOD FOR PRODUCING MAIN CHAIN POLYMER, METHOD FOR PRODUCING OPTICAL FILM, AND MULTILAYER FILM | TOSOH CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-12187682-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4455128-A1 | MAIN CHAIN POLYMER, OPTICAL FILM, METHOD FOR PRODUCING MAIN CHAIN POLYMER, METHOD FOR PRODUCING OPTICAL FILM, AND MULTILAYER FILM | Tosoh Corporation (JP) | 2024-10-30 | — | — | EP | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118434793-A | Main chain polymer, optical film, method for producing same, and multilayer film | 东曹株式会社 | 2024-08-02 | — | — | CN | disclosed |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2024-03-28 | — | — | US | disclosed |
| US-11724989-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
| EP-3307068-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160362378-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-15 | — | — | US | disclosed |
| WO-2016201426-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20110250254-A1 | ANTIMICROBIAL COMPOSITIONS AND USES | UNIVERSITETET I OLSO (NO) | 2011-10-13 | — | — | US | disclosed |
| EP-2346330-A1 | ANTIMICROBIAL COMPOSITIONS AND USES | Universitetet I Oslo (NO) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010040839-A1 | ANTIMICROBIAL COMPOSITIONS AND USES | UNIVERSITETET I OSLO (NO) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187682-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | LMNA 2639/4885TSHR 3384/4885GSK3B 3039/4885 |
| US-20110250254-A1 | ANTIMICROBIAL COMPOSITIONS AND USES | CBR3, C5, C3AR1 | LMNA 4349/4885TSHR 170/4885GSK3B 4849/4885 |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | LMNA 3753/4885TSHR 3048/4885GSK3B 3521/4885 |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | LMNA 2639/4885TSHR 3384/4885GSK3B 3039/4885 |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | LMNA 3753/4885TSHR 3048/4885GSK3B 3521/4885 |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A8 | LMNA 3182/4885TSHR 3462/4885GSK3B 3736/4885 |
| US-20250179243-A1 | MAIN CHAIN POLYMER, OPTICAL FILM, METHOD FOR PRODUCING MAIN CHAIN POLYMER, METHOD FOR PRODUCING OPTICAL FILM, AND MULTILAYER FILM | C9, RNF4, F12 | LMNA 698/4885TSHR 2163/4885GSK3B 3380/4885 |
| US-20160362378-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A3, SLC16A1, MCTS1 | LMNA 3600/4885TSHR 2963/4885GSK3B 2847/4885 |
| US-11724989-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | LMNA 2639/4885TSHR 3384/4885GSK3B 3039/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | LMNA 1910/4885TSHR 2490/4885GSK3B 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.